trending Market Intelligence /marketintelligence/en/news-insights/trending/tqpAuyBq0MY2Yj0qm-EqPg2 content esgSubNav
In This List

US FDA to expedite Mesoblast's heart failure treatment in patients with implants

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


US FDA to expedite Mesoblast's heart failure treatment in patients with implants

Mesoblast Ltd's approval application for its mesenchymal precursor cell, or MPC, therapy has been expedited as the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to the product.

The MPC therapy aims to treat heart failure patients with left ventricular systolic dysfunction and left ventricular assist devices.

The designation also allows for priority review of the therapy.

The U.S. FDA granted the designation based on the preliminary results of a placebo-controlled trial. The study reported improved heart function and improved survival rates in patients with heart implants along with a delay in internal bleeding caused by the same.

Mesoblast is conducting a phase 2b trial for the product. The company expects to have results from the trials by the first quarter of 2018.